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Abstract
Backgrounds: Breast cancer is the most prevalent cancer among women. Breast cancer imposes a considerable
economic burden on the health system. This study aimed to compare the cost of breast cancer among patients
who referred to private and public hospitals in Iran (2017).
Methods: This was a prevalence-based cost of illness study. A total of 179 patients were selected from private and
public hospitals using the census method. The researcher-constructed checklist was used for data collection. Data
were analyzed using SPSS software version 22.
Results: The estimated total mean (SD) direct cost of patients who referred to the private hospital and the public
hospital was $10,050 (19,480) and $3960 (6780), respectively. Further, the total mean indirect cost of patients who
referred to the private hospital was lower than those referring to the public hospital at $1870 (15 % of total costs)
and $22,350 (85 % of total costs), respectively. These differences were statistically significant (P < 0.05).
Conclusions: Breast cancer imposes a substantial cost on patients, health insurance organizations and the whole
society in Iran. Therefore, the adoption of effective measures for the prevention and early diagnosis of breast cancer
is urgently needed.
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Highlights
 Hospitalization and outpatient costs in the private
hospital were higher compared with the public
hospital.
 Indirect costs were higher in the public hospital
compared with the private hospital.
 A statistically significant difference was found
between supplementary insurance status and total
medical direct cost (P < 0.05).
Background
Cancer is a leading cause of death worldwide. The num-
ber of cancer cases and deaths is projected to grow rap-
idly due to population ageing and adopt lifestyle
behaviours that increase cancer risk. This is especially
important in low- and middle-income countries as they
undergo an economic transition [1]. The estimated num-
ber of new cases and cancer deaths was 2,088,849 and
626,679, respectively, worldwide in 2018 [2].
Breast cancer is a major public health problem, and
1.7 million new cases are diagnosed per year. It has been
shown that almost 60 % of deaths from breast cancer
occur in developing countries [3, 4]. In 2018, breast can-
cer was the most commonly diagnosed cancer in women
(24.2 %, i.e. nearly one in 4 of all new cancer cases diag-
nosed in women worldwide were breast cancer) [5]. In
2018, it was estimated that 627,000 women died from
breast cancer, contributing approximately 15 % of all
cancer deaths among women [5]. It has been estimated
that the incidence of women breast cancer worldwide
will reach approximately 3.2 million new cases per year
by 2050 [4].
Breast cancer in developing countries represents one-
half of all breast cancer cases and 62 % of cancer mortal-
ity [6]. In Iran, breast cancer is the fifth leading cause of
cancer mortality [7–9]. According to GLOBOCAN data-
base 2018, the number of new cases, deaths and 5-years
prevalence from breast cancer for women in Iran was es-
timated to be 13,776, 3526 and 40,825, respectively [10].
In the last 30 years, the probability of breast cancer inci-
dence for individuals aged 15–79 years in Iran has in-
creased, according to the statistics [11]. According to the
statistics, 6160 breast cancer cases are diagnosed in the
country each year, and 1063 cases result in death [12].
In 2035 compared to 2012, the number of new cases will
be nearly two times greater [13].
Breast cancer imposes a considerable economic bur-
den on societies [14–16]. For example, the total cost
of breast cancer was more than three times the total
cost of prostate cancer [17]. A study by Figueiredo
et al. indicated that public healthcare costs increased
between 2004 and 2014, and the correlation between
breast cancer and public healthcare costs was positive,
mainly influenced by governmental strategies [18].
Breast cancer imposes a significant financial burden
on healthcare systems of Iran [19, 20]. Policymakers
and health planners are interested in understanding
the economic burden of illnesses to assess the optimal
allocation of health resources to various diseases and
estimate the potential costs and benefits of public
health interventions [20].
Cost of Illness (COI) studies indicate the import-
ance of a particular disease and provide a baseline for
assessing new interventions [20] and financial losses
as a result of illness [21]. The aim of the COI-studies
is providing an estimate of how much society spends
on a particular disease and identifying different cost
components [22]. The COI can be used as a criterion
for decision making in allocating limited budgets and
resources for governmental health policies in effective
control of diseases [21]. A comprehensive economic
analysis demands consideration of both direct and in-
direct costs such as productivity losses as a result of
individuals unable to work because of hospitalization
or outpatient visits, and also premature death arising
from the illness [21].
In future, the cost of cancer care will increase as new
sophisticated, expensive treatment modalities are
adopted to raise the standard of care [23]. Breast cancer
is on the rise in Iran, and since patients are mostly diag-
nosed at more advanced stages of the disease [24, 25],
mortality resulting from breast cancer is high [26]. So,
the presentation of accurate data about the economic
burden of the disease will allow informed decision mak-
ing by health care policymakers in Iran about the pre-
vention and treatment of the disease. Therefore, the
objective of this study was to compare the cost of breast
cancer among patients who referred to private and pub-
lic hospitals in Iran in 2017.
Methods
Database and study population
This was a prevalence-based cost of illness study, which
was conducted from the societal perspective using
bottom-up approach costing.
The statistical population in this study included all pa-
tients with breast cancer. One hundred seventy-nine pa-
tients with breast cancer who admitted to the private
hospital (N = 103) and the public hospital (N = 76) in
Rasht (a city in the north of Iran) between Aug 2016
and Aug 2017 included in this study.
Cost assessment
The cost of illness is divided into three general categor-
ies: direct costs, indirect costs, and intangible costs. In
this study, we mainly focus on the first two cost
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categories. The direct costs consist of medical costs and
non-medical costs. The former includes medical care ex-
penditures for diagnosis, treatment, and rehabilitation,
etc., while the latter includes the consumption of non-
healthcare resources like transportation, household ex-
penditures, relocating. Indirect costs include lost prod-
uctivity due to premature deaths and missed workdays
and decreased workplace productivity due to morbidity.
Finally, intangible costs include the cost of pain and suf-
fering in patients and their families and relatives. In this
study, intangible costs were not calculated.
In this study, the economic burden of breast cancer
was assessed by calculating direct medical costs, direct
nonmedical costs, and indirect costs. Data related to the
hospitalization part of direct medical costs were ex-
tracted from patients’ records and data related to the
outpatient part of direct medical costs, direct nonmedi-
cal costs and indirect costs were obtained via an inter-
view with patients and their family members,
respectively. The researcher-made checklist was used for
data collection. The initial draft of the checklist ex-
tracted from two records: (1) “Cost-of-illness studies - a
primer” [27] and (2) “Cost-of-illness studies: concepts,
scopes, and methods” [28]. Then, to complete the check-
list, we interviewed 5 oncologists, 2 researchers who had
conducted at least one cost of illness study, 2 professors
in the field of Health Economics and 8 breast cancer pa-
tients. The checklist consists of demographic variables
(age, marital status, monthly income status, educational
status, job status, supplemental insurance status, and the
type of basic insurance), duration of the disease and
treatment type and questions related to costs compo-
nents incurred by patients during cancer diagnosis, and
treatment procedures. In this study, direct medical costs
were valued based on the medical tariffs of diagnostic
and therapeutic services.
Indirect costs include the monetary value of re-
sources loses due to morbidity and mortality. There
are three approaches to estimate indirect costs: the
human capital approach (HCA), the friction cost ap-
proach (FCA) and the willingness to pay approach
(WTP). HCA measures the lost production, in terms
of lost earnings, of a patient or caregiver. FCA mea-
sures only the production losses during the time it
takes to replace a worker, and WTP measures the
amount an individual would pay to reduce the prob-
ability of illness or mortality. HCA is the most com-
mon approach used to calculate the indirect costs of
an illness. A criticism of this approach is that certain
groups are assigned a higher value than others. A
criticism of WTP is that this approach is often diffi-
cult to implement in COI studies. For specific dis-
eases, extensive surveys of people’s preferences are
needed, which the results rely heavily on the type of
question and people’s responses to very specific
hypothetical questions. For communicable diseases,
surveys may ignore the cost of the disease because
of externalities (cost of externalities incurred by dis-
ease). The WTP, therefore, is often not feasible for a
cost-of-illness study. Proponents of the FCA criticize
the HCA for overvaluing the indirect costs, claiming
that the productivity losses are often eliminated after
a new employee is trained and can replace the
former employee. However, the FCA is rarely used
because it requires extensive data to estimate losses
in the friction period. On the other hand, the esti-
mated cost is strongly influenced by the labour sup-
ply situation [27, 29].
In this study, indirect costs were calculated based on
the HCA. These costs were estimated by summing two
parts: (1) The costs of lost productivity due to patients
and their families’ missed workdays and (2) the cost of
premature death due to breast cancer. First, in order to
estimate the cost of missed workdays per patient, we cal-
culated the average number of missed workdays by pa-
tients and their families because of breast cancer and
then multiplied by the minimum daily wage rate (310,
000 (2017)), in this way we estimated the cost of missed
workdays per patient. Also, by having the number and
the mean age of premature death and retirement age (60
years old) in Iran, the total number of years lost due to
premature death resulting from breast cancer was calcu-
lated and multiplied by the number of days of the year
and the minimum daily wage rate, in this way the cost of
premature death was calculated. Finally, the total cost of
lost productivity calculated by summing these two parts.
The equations used for indirect costs calculation are
as follows:
The cost of missed workdays ¼ the mean ðpatients missed workdays
þ patient family’s missed workdaysÞ  minimum daily wage rate
ð1Þ
C ¼ the mean fðretirement age−age at premature deathÞ
 ðthe number of patients who died  sample sizeÞg
 ðminimum daily wage rate the number days of the yearÞ
ð2Þ
To recall bias prevention, patients’ treatment process
were followed up every two months for one year.
Unit costs
All costs in this study were expressed as US Dollars
based on the Exchange rate of Central Bank of the Is-
lamic Republic of Iran (US$ 1 = 31,389 Rials (2017)). As
the time horizon of the study was one year, costs are not
discounted (Table 1).
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Data analysis
Data were analyzed using SPSS software version 22 and
excel (2016). Descriptive statistics (mean (SD), frequency,
and percent) were used to assess the status of the demo-
graphic variables. K-S test (Kolmogorov-Smirnov) was ap-
plied to assess the normality of data. Since the P-Value for
all variables was less than 0.05 (P < 0.05), non-parametric
tests, including Mann-Withney and Kruskal-Wallis, were
used to assess the association between demographic vari-
ables and costs. The Spearman correlation coefficient also
was used to examine the correlation between age at diag-
nosis and costs. A multivariate regression model was used
to control for confounding factors.
One-way sensitivity analyses were conducted to assess the
effects of varying key components of direct medical costs on
the total direct medical costs. The variation ranges were
established based on the ± 50% of the index value; index
value was set based on the mean total direct medical costs.
Results
A total of 179 patients with breast cancer were included
in the analysis. The majority of patients were covered by
the basic insurance (98.9 %), and only 36.3 % of patients
were covered by supplemental insurance. Most of the
patients (64.2 % ) held a diploma degree and more than
half of the patients were non-natives (54.2 %). A
Table 1 Cost categories and sources of applied unit costs
Sector Service / Goods Data source Units Monetary values
(unit costs)
Surgery costs Operating room consumables & equipment, Operating
room medication, physician (surgeon) work, anaesthetic
Medical
records
Relative value unit/ Current
Procedural Terminology
Medical tariffs
Hoteling costs Cost of non-physician human resources, depreciation,
repairs and maintenance, food, energy, other goods
and services not included in the billing separately
Medical
records
Days of hospital stay Reimbursement
schedule
















Intravenous chemotherapy cost, cost of faculty












Chemotherapy costs Manpower cost, drug cost Questionnaire Quantity Reimbursement
schedule
Radiotherapy costs Manpower cost, equipment cost Questionnaire Quantity Reimbursement
schedule




Physiotherapy cost, Injection cost, over-the-counter
medication price, prescription medication cost,






Costs that patients and caregivers incurred due to
commuting to treatment centres
Questionnaire Quantity Consumer price
Accommodation costs (costs that patients and caregivers incurred due to
residing in hotel or hostel for receiving services in
other cities)
Questionnaire Quantity Consumer price
The cost of missed
workdays (patient)
Productivity losses resulting from the disease Questionnaire Days The current
average wage
in the country
The cost of missed
workdays (family)
Productivity losses of caregivers for patient care Questionnaire Days The current
average wage
in the country
The cost of premature
death
Productivity loss due to premature death Questionnaire Years The current
average wage
in the country
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statistically significant difference was found between
supplemental insurance status and total medical direct
cost (P < 0.05) Table 2.
The mean(SD) of age at diagnosis, age and age at
death was estimated at 45.41 (9.38), 47.98 (10.08) and
49.94 (11.80), respectively. The estimated mean(SD)
number of hospital admission and the length of hospital
stay of patients who referred to the private hospital was
1.35 (0.50) and 2.71 (2.49), respectively whereas those
who referred to the public hospital was higher at 1.48
(085) and 8.63 (1049), respectively. Additionally, 10.7 %
of patients who referred to the private hospital and 6.6 %
of those referring to the public hospital postponed their
treatment process for more than two months due to fi-
nancial barriers.
As shown in Table 3, direct costs in private hospital
accounted for 84.04 % of total costs and almost 1.92
times GDP per capita. In contrast, direct costs in public
hospital accounted for 17.22 % of the total cost and
75.80 % of GDP per capita.
The direct medical costs of breast cancer patients who
referred to the private hospital and the public hospital
were $9880 (82.90 % of the total costs and 1.89 times
GDP per capita) and $3620 (13.74 % of the total costs
and 69.29 % of GDP per capita), respectively. The
hospitalization costs and outpatient costs of patients
who referred to the private hospital were higher than
those referring to the public hospital. The highest com-
ponent of hospitalization costs of patients who referred
to the private hospital was related to surgery cost at
$980 (53.73 % of the total hospitalization cost), whereas
that of patients who referred to the public hospital was
related to hoteling costs at $380 (30.26 % of the total
hospitalization cost).
Moreover, medication cost had the lowest rate in
breast cancer patients who referred to the private hos-
pital at $30 In contrast, the lowest cost among those re-
ferring to the public hospital was related to the
diagnostic cost at $100. In summary, outpatient costs
were the main component of the direct medical costs for
breast cancer patients who referred to the private hos-
pital and the public hospital.
Besides, the total mean nonmedical direct cost of pa-
tients who referred to the private hospital and the public
hospital was $170 (1.39 % of the total costs) and $340
(1.29 % of the total costs), respectively. The highest com-
ponent of the direct nonmedical cost of patients who re-
ferred to the private hospital and the public hospital was
attributed to commuting and food costs at $150and
$250, respectively Table 3.
The total mean indirect cost of patients who referred
to the private hospital was $1870, making up 15.69 % of
the total cost and 0.35 of GDP per capita, and for those
referring to the public hospital was $ 22,350, comprising
84.95 % of the total costs and 4.28 times GDP per capita.
This difference was statistically significant (P < 0.05). Ac-
cording to our findings, the total missed workdays of pa-
tients, and patients’ families who referred to the private
Table 2 Demographic characteristics and direct medical cost (N = 179)
Variable Modes N (%) $Mean (SD) P-Value
Age < 40 years 39 (21.8) 9296 (20,500) 0.32
40–60 years 121 (67.6) 6885 (14,600)
> 60years 19 (10.6) 4930 (8640)
Marital status Single 15 (8.4) 5737 (9910) 0.30
Married 164 (91.6) 7330 (15,980)
Education status Illiterate 40 (22.1) 11,230 (16,100) 0.06
Diploma 115 (64.2) 10,775 (17,390)
Academic education 24 (13.7) 24,695 (39,880)
Supplemental Insurance status Yes 65 (36.3) 11,427 (23,500) 0.001*
No 114 (63.7) 4795 (7280)
Type of Basic insurance Social security insurance 84 (46.9) 7635 (16,710) 0.79
Iranian health insurance 63 (35.0) 7690 (17,520)
Relief foundation insurance 19 (10.7) 3595 (4095)
Other basic insurances 13 (7.3) 6040 (7560)
Habitation status Native (patients resident in the city of Rasht) 82 (45.8) 6857 (16,060) 0.92
Non-native (non-Rasht patients) 97 (54.2) 7480 (15,170)
Type of hospital Private hospital 103 (57.5) 9885 (19,425) 0.001*
Public hospital 76 (42.5) 3620 (6410)
*P < 0.05 was considered as significant
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hospital were estimated to be 66 and 123 days while
those of patients who referred to the public hospital esti-
mated at 14 and 97 days, respectively. Both in the private
hospital and the public hospital, the mean cost of lost
workdays was considerably higher for family caregivers
than for the patients themselves.
A multivariate regression model was used to con-
trol for age, education status, marital status, habita-
tion status, type of basic insurance and
supplemental insurance status. The results of the
regression model are presented in Table 4.
Hospitalization costs in the public hospital were
510, significantly lower as compared with the pri-
vate hospital. Besides, outpatient costs and direct
medical costs in the public hospital respectively
were 3290 and 5270, lower than the private hospital,
but this was not statistically significant.
The reimbursement rate of basic insurance for patients
who referred to the public hospital was higher than
those referring to the private hospital (90.68 % VS
Table 3 Mean (SD) and Median (Interquartile Range) of breast cancer costs ($)
Variable Mean (SD) Median (Interquartile Range) P-
ValuePrivate Hospital Public Hospital Private Hospital Public Hospital
Surgery costs 980 (610) 195 (335) 950 (225) 0 (350) 0.001*
Hoteling costs 360 (420) 380 (550) 210 (250) 170 (400) 0.02*
Diagnostic costs 300 (230) 105 (160) 310 (280) 60 (130) 0.001*
Visit Costs 35 (95) 140 (230) 0 (5) 70 (185) 0.001*
medication costs 30 (80) 265 (530) 15 (20) 40 (340) 0.001*
Other hospitalization costsa 120 (290) 160 (320) 140 (170) 70 (160) 0.01*
Total hospitalization cost 1830 (940) 1250 (1550) 1620 (700) 770 (1470) 0.001*
Outpatient diagnostic costs 2430 (7440) 425 (940) 0 (1530) 0 (480) 0.12
Chemotherapy costs 760 (1200) 195 (540) 15 (1430) 0 (0) 0.001*
Radiotherapy costs 550 (1340) 160 (710) 0 (60) 0 (0) 0.001*
Outpatient visit costs 460 (1120) 100 (320) 0 (380) 0 (190) 0.01*
Other outpatient costsb 3865 (11,690) 1480 (60) 0 (1810) 0 (730) 0.16
Total outpatient costs 8060 (19,370) 2365 (6430) 2350 (7725) 0 (2670) 0.004*
Total medical direct costs 9880 (19,425) 3620 (6410) 4250 (8190) 1770 (3730) 0.001*
Commuting and food costs 150 (690) 250 (700) 0 (15) 0 (120) 0.37
Accommodation costs 10 (125) 920 (570) 0 (0) 0 (0) 0.36
Total non-medical direct costs 170 (700) 340 (900) 0 (15) 0 (120) 0.41
Total direct costs 10,050 (19,480) 3960 (6780) 4490 (8290) 1935 (4715) 0.001*
The cost of missed workdays (patient) 655 (2690) 140 (1220) 0 (0) 0 (0) 0.05*
The cost of missed workdays (family) 1215 (3043) 960 (2690) 0 (590) 0 (0) 0.08
The total of missed workdays 1870 (4930) 10,100 (3080) 0 (830) 0 (0) 0.03*
The cost of premature death 0 21,250 (11,630) 0 (0) 10,640 (19,110) -
Total indirect costs 1870 (4930) 22,350 (18,630) 0 () 10,640 (19,110) 0.03*
Total costs 11,960 (20,530) 22,970 (12,660) 5620 (9230) 11,340 (22,540) 0.001*
*P < 0.05 was considered as significant
aintravenous chemotherapy cost, cost of faculty members, mastectomy cost, Forensic medicine cost, hospital cost
bPhysiotherapy cost, Injection cost, over-the-counter medication price, prescription medication cost, paying extra cost to the surgeon, cost of caregivers,
vitamin cost
Table 4 Multivariate regression results of direct medical costs
Dependent variable Independent variables B(SE) Beta p-value
Medical direct costs Hospital (reference group = public) -5270 (6420) -0.13 0.41
Hospitalization costs Hospital (reference group = public) -510 (245) -0.30 0.04*
Outpatient costs Hospital (reference group = public) -3290 (6020) -0.09 0.59
*P < 0.05 was considered as significant
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37.85 %). Additionally, 26.77 % and 6.39 % of costs were
paid by patients who referred to the private hospital and
the public hospital, respectively Table 5.
The total mean cost of breast cancer among patients
who referred to the public hospital was estimated at $
22,970, which was equivalent to 4.4 times GDP per
capita (Gross Domestic Product per capita = 5219.1 USD
(2016), while that of patients who referred to the private
hospital was $11,960, which was equivalent to 2.29 times
GDP per capita. As shown in Table 6, the major compo-
nent of the total costs of patients who referred to private
hospitals was related to the direct costs at 84.30 % (al-
most 5.6 times greater than those referring to the public
hospital) which was equivalent to 1.92 times GDP per
capita. In comparison, the major component of the total
costs of patients who referred to the public hospitals was
related to the indirect costs at 84.95 % (almost 5.41 times
greater than those referring to the private hospital)
which was equivalent to 4.28 times GDP per capita.
Variations in sensitivity analysis results are listed in
Table 7.
In our study, midline (= 4236.37) was obtained by
summing direct medical costs components. Low and
high value was calculated as follows:
(3) Low case = mean of each component – (0.5*base
case).
(4) High case =mean of each component + (0.5*base
case).
Tornado diagrams are presented for the seven main
components of direct medical costs (Fig. 1). The results
demonstrated that diagnostic, surgery and chemotherapy
costs were most important in driving breast cancer
costs.
Discussion
In this study, the estimated mean of age at diagnosis, the
age of patients and age at death was 45.41, 47.98 and
49.94 years old, respectively. In our study, the mean age
of patients was 47.98 years old, while in Davari et al.
(2013), the mean age of patients estimated at 49 years
old, in Iran [30]. So it can be concluded that the age of
breast cancer onset has decreased in Iran in recent years.
The average mortality age of breast cancer is still lower
than other cancers, and the economic burden of this dis-
ease will rise in the predictable future, according to one
study in Japan [21].
In this study, the total mean cost of breast cancer
among patients who referred to the public hospital was
1.92 times greater than those referring to the private
hospitals (76,630 PPP current international $ VS 41,460
PPP current international $). The results showed that
direct costs were the major component of the total costs
of patients with breast cancer who referred to the private
hospital, whereas the major component of the total cost
of those referring to the public hospital was related to
the indirect costs.
The indirect cost of patients who referred to the public
hospital was 11.94 times as much as than those referring
to the private hospital, and this difference was statisti-
cally significant. In contrast, the estimated mean medical
direct cost of patients who referred to the private hos-
pital was 2.73 times greater than those referring to the
public hospital (34264.12 PPP $ VS 12536.16 PPP
current international $). In the study of T. A. Dinesh
et al., in India, there was a significant difference in the
direct cost of care for cancer in private hospitals ($27,
425 vs. $21,2320), whereas the indirect cost of care for
cancer was significantly higher in government hospitals
($10,340 vs. $6565) [31]. A study by Kounichika et al. in
Japan indicated that the mortality costs accounted for
65–70 % of the total cost [21], which the results of these
studies are in line with our results.
The difference between direct and indirect costs in pa-
tients referred to private and public hospitals may be
due to several reasons. Firstly, premature death was the
major component of the total indirect cost of breast can-
cer patients who referred to the public hospital, whereas
that did not occur among breast cancer patients in the
private hospital. This may be because private hospitals
offered better services, resulting in a higher survival rate
and a lower mortality rate. Besides, given that the mean
age of patients with breast cancer referring to the public
hospital (49.776.66 (9.89)) was higher as compared with
those referring to the private hospital (46.66 (10.06)),
and this difference was statistically significant (p < 0.05),
the high mortality rate in the public hospital can be be-
cause most of the older patients referred to the public
hospital. On the other hand, patients with advanced-
stage cancer likely referred more to public hospitals for
receiving services. Secondly, none of the patients who
referred to the public hospital had supplementary insur-
ance, while most of the patients who referred to the
Table 5 Mean (SD) of hospitalization costs based on the type of payer ($)
Type of payer Private Hospital The total hospitalization cost (%) Public Hospital The total hospitalization cost (%)
Basic insurance 690 (870) 37.85 1150 (1460) 90.68
Supplemental insurance 645 (695) 35.36 0 0
Subsidy 0 0 37 (100) 2.92
Patient 490 (645) 26.77 80 (90) 6.39
Afkar et al. BMC Health Services Research          (2021) 21:219 Page 7 of 11
private hospital, in addition to basic health insurance,
were covered by supplemental insurance. Supplemental
insurance has increased patients access to more ad-
vanced and expensive treatment services and has made
services more inelastic by reducing the patients’ co-
payment or have led to increased induced demand. In
this study, the correlation between direct medical costs,
outpatient costs, chemotherapy costs and age at diagno-
sis was statistically significant and negative at P < 0.05.
Thirdly, tariffs in the private sector are 2–4 times
higher than that of the public sector. Therefore, direct
medical costs are higher in patients referring to the pri-
vate sector.
Of note, in Iran, only people who have better socio-
economic status and better income level are able to af-
ford supplemental health insurance and refer to the pri-
vate sector for receiving treatment, which in turn cause
they receive more expensive and advanced services.
Hence, it may cause the mortality rate among those to
refer to the private hospital to be lower and incur lower
indirect costs, but due to more treatment services
utilization, they are more likely to incur greater direct
medical costs than those referring to the public hospital.
Of the direct medical costs, outpatient costs were
higher than hospitalization costs in private and public
hospitals. The outpatient cost of patients who referred
to the private hospital was 3.4 times greater than those
referring to the public hospital. The major component
of outpatient diagnostic costs of patients who referred to
the private and the public hospitals was related to diag-
nostic costs. Our study results suggest that more atten-
tion should be paid to the management of outpatient
costs for breast cancer patients in both private and pub-
lic hospitals. The study by Allaire et al. in the US re-
ported that the outpatient costs caused by breast cancer
were equivalent to 94 % of the total cost of breast cancer
[32]. In the study of Ekwueme et al., the estimated
monthly direct medical costs for breast cancer treatment
among younger women enrolled in Medicaid was $5,711
per woman. The estimated monthly cost for outpatient
services was $4,058, for inpatient services was $1,003,
and for prescription drugs was $539 [33].
Furthermore, the hospitalization costs of patients who
referred to the private hospital were 1.46 times greater
than those referring to the public hospital. This differ-
ence may, in part, be because of the different tariffs or
difference in the type of provided services. The most
component of total hospitalization cost of patients who
referred to the private hospital was related to surgery
cost, whilst that of patients who referred to the public
hospital was attributable to hoteling cost. In a study by
Davari et al., in 2013, in Iran, the main driver of the
Table 7 Model variables: Total direct medical costs
Variables Base casea Low value High value
Medication costs 131.65 65.82 197.4
Hoteling costs 367.15 183.57 550.72
Radiotherapy costs 386.19 193.09 579.28
Visit Costs 391.14 195.57 586.71
Chemotherapy costs 520.68 260.34 781.03
Surgery costs (Mastectomy) 648.00 324.00 972.00
Diagnostic costs 1791.54 895.77 2687.31
aMean of each variable, Mid line = 4236.37
Table 6 Main costs of breast cancer compared with mean total cost and GDP per capita
Costs Private hospital Public hospital
Total costs (%) GDP per capita (%) Total costs (%) GDP per capita (%)
Medical direct costs
Total hospitalization costs 15.33 35.02 4.75 23.95
Total outpatient costs 67.62 154.48 8.99 45.33
Total medical direct costs 82.90 189.39 13.74 69.29
Non- medical direct costs
Commuting and food costs 1.29 2.95 0.94 4.74
Accommodation costs 0.10 0.23 0.35 1.76
Total non-medical direct costs 1.39 3.19 1.29 6.51
Total direct costs 84.30 192.59 15.04 75.80
Indirect costs
The cost of missed workdays (patient) 5.50 12.56 0.53 2.68
The cost of missed workdays (patient’s family) 10.19 23.28 3.64 18.37
The total cost of missed workdays 15.69 35.84 4.17 21.06
The cost of premature death 0 0 80.78 407.14
Total indirect costs 15.69 35.84 84.95 428.20
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costs were related to drug therapy [30]. In the study of
Omondi Michelle et al., in 2016, patients on chemother-
apy alone cost an average of $1364.3; while those treated
with surgery cost an average of $1265.6, and those on
radiotherapy $1175.1 [34]. A study by Elias et al. showed
that the average annual cost of cancer drugs was 6.475$
per patient, which the highest amount of medication
costs were related to breast cancer [35].
In the private hospital, the mean of chemotherapy
cost for those who had received chemotherapy esti-
mated at $1450 per patient, making up 14.67 % of the
total medical costs while in the public hospital was
$550 per patient, which accounted for 15.13 % of the
total medical costs. Likewise, The mean of radiother-
apy cost for those who had received radiotherapy in
the private hospital and the public hospital was esti-
mated to be $680 (6.88 % of the total medical costs)
and $189 (5.22 % of the total medical costs) per pa-
tient, respectively. Moreover, the total direct nonmed-
ical cost of patients who referred to the public
hospital was 2.03 times greater than those referring to
the private hospital. At both hospitals, commuting
costs accounted for the highest component of pa-
tients’ total nonmedical direct cost.
The total cost of missed workdays for the patient and
the patient’s family, who referred to the private hospital
was 1.7 times greater than those referring to the public
hospital. Both in the private and the public hospital, the
cost of missed workdays of patient’s family members
was greater than patients themselves. These costs (op-
portunity cost) are imposed on patients’ families in real
terms but are hidden from policymakers’ view.
In our study, basic insurance played an important role
in the reimbursement of direct medical costs and redu-
cing the proportion of out-of-pocket expenses in direct
medical costs. The majority of breast cancer costs in
public hospitals was paid by basic insurance (90.68 %),
6.39 % of the costs were paid by the patient, and only a
small proportion was paid from the targeted subsidy
plan by the government (2.92 %). To the contrary, in the
private hospitals, %35.36 of costs was reimbursement by
supplemental insurance, 37.85 % of costs was reimburse-
ment by basic insurance, and the remaining 26.77 % of
costs (6.04 greater than those referring to the public
hospitals) was paid by patients. The total out of pocket
payments in the private hospital estimated at $3881.23
(approximately 0.38 of total direct costs and 2.83 times
higher than in the public hospital), while in the public
hospital was $1367.19 (about 0.34 of total direct costs).
It is important to note that although most of the can-
cer patients in the private sector were covered by sup-
plemental insurance, they paid higher co-payments.
Since tariffs in the private sector are 2–4 times higher
than that of the public sector, patients referring to pri-
vate hospitals paid more out of pocket payments despite
supplemental insurance. Therefore, these patients are
likely to have better socio-economic status and more
ability to pay. On the other hand, despite higher costs,
these patients may prefer to go to private hospitals be-
cause of the shorter waiting time and better service
quality.
Since the present study was performed at cross-
sectional and prevalence-based method, matching was
not conducted between patients referring to the pub-
lic and the private hospitals in terms of age, income
level and disease stage and also the effect of con-
founding variables was not controlled. Since it is not
possible to conclude with any certainty, it is necessary
to investigate the cause of this difference in costs and
mortality rate between patients referring to the public
and the private hospitals in future studies using a
perspective and controlled design. In Multivariate re-
gression model after adjusting for confounding vari-
ables (e.g., age, education status, marital status,
habitation status, type of basic insurance and supple-
mental insurance status), hospitalization costs in
Fig. 1 Tornado diagram for one-way sensitivity analysis
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patients referring to private hospitals were signifi-
cantly higher than those referring to the public hos-
pital. Moreover, our sensitivity analyses showed that
diagnostic costs are the key drivers in breast cancer
costs. Therefore, it seems the management of diag-
nostic costs, more than other direct medical costs
component, can help to reduce the costs of breast
cancer.
Limitations
This study had several limitations. First, since some pa-
tients refused to answer the questions asked of them, the
selection bias (sampling bias and attrition) of respon-
dents in reviewing the costs could not be avoided. Sec-
ond, the indirect costs consisted of only the missed
workdays and premature mortality, which would greatly
undervalue the indirect economic burden of illness. The
lack of data on permanent leaving the job by patients
and caregivers during the recovery period could also
underestimate the indirect cost estimates. Third, the cost
of breastfeeding was not calculated due to the paucity of
data. Fourth, intangible economic costs of breast cancer
patients and their families, including the pain, sorrow,
were not included because they are difficult to convert
into a monetary value [36]. Given this was a cross-
sectional and prevalence-based study, matching was not
conducted between patients referring to the public and
the private hospitals in terms of age, income level and
disease stage and also the effect of confounding variables
were not controlled. An additional limitation is that this
study conducted in only two private and public hospitals
that can limit the generalization of study findings to all
private and public sector.
Policy implications
Given that the cost of premature death in the private
hospital was zero, it is not possible to conclude with cer-
tainty whether cancer patients who referred to the public
hospital were at the final stage of the disease or bene-
fited from better services or both? If the low mortality
rate and low indirect costs in patients referred to the
private hospital be attributed to the quantity and quality
of services provided to cancer patients referring to the
private sector and considering the high share of indirect
costs of total costs in patients referred to the public hos-
pital, it is necessary that health policymakers take the
necessary measures to improve the quantity and quality
of public sector services. Also, despite the insurance
coverage, patients suffer a high amount of OOP pay-
ment, a substantial and wide-ranging effort is needed to
support breast cancer patients. This suggests that insur-
ance policies need to be revised to increase financial
support among cancer patients, especially for those who
are currently uninsured. It is recommended that the
results of this study be used in future studies to evaluate
the cost-effectiveness of screening interventions, early
detection and preventive interventions, and health pol-
icymakers take an appropriate policy to reduce the eco-
nomic burden of this disease. It is also suggested that
future studies should examine whether the higher costs
in private hospitals is due to disparities in tariffs of the
private and public sector or due to greater quantity and
quality services provided in private hospitals.
Conclusions
Breast cancer imposes a substantial economic burden on
patients at private and at public hospitals, healthcare sys-
tem and society. Indirect costs were considerably higher
for breast cancer patients and their caregivers referring
to the public hospital, especially in terms of premature
mortality than those referring to the private hospital,
which can show a significant proportion of the total
costs. Because indirect costs do not impose on the
health system and health insurance organizations, health
policymakers do not pay enough attention to these costs.
Therefore, these costs must be addressed at the macro
level of economic policymaking. Support strategies also
should be adopted for cancer patients and their family
members at parliament and government level, and un-
employment insurance, improved for cancer patients.
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